Flexion Therapeutics (FLXN)

9.12  -0.02 (-0.22%)

After market: 9.121 +0 (+0.01%)

Fundamental Rating

2

FLXN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. FLXN has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, FLXN is valued expensive at the moment.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year FLXN has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -46.22%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -78.17%
PM (TTM) -100.33%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

FLXN has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, FLXN has about the same debt to assets ratio.

2.2 Solvency

FLXN has an Altman-Z score of -4.56. This is a bad value and indicates that FLXN is not financially healthy and even has some risk of bankruptcy.
FLXN has a Debt/Equity ratio of -3.04. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity -3.04
Debt/FCF N/A
Altman-Z -4.56
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

FLXN has a Current Ratio of 4.38. This indicates that FLXN is financially healthy and has no problem in meeting its short term obligations.
FLXN has a Quick Ratio of 4.05. This indicates that FLXN is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.38
Quick Ratio 4.05

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.59% over the past year.
The Revenue has grown by 21.13% in the past year. This is a very strong growth!
FLXN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 519.40% yearly.
EPS 1Y (TTM)33.59%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-20.66%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y519.4%
Revenue growth 5YN/A
Revenue growth Q2Q-9.86%

3.2 Future

FLXN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.86% yearly.
FLXN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 36.37% yearly.
EPS Next Y18.99%
EPS Next 2Y20.75%
EPS Next 3Y19.88%
EPS Next 5Y7.86%
Revenue Next Year26.13%
Revenue Next 2Y35.91%
Revenue Next 3Y35%
Revenue Next 5Y36.37%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FLXN. In the last year negative earnings were reported.
Also next year FLXN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -7.41

4.3 Compensation for Growth

FLXN's earnings are expected to grow with 19.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.75%
EPS Next 3Y19.88%

More info and screens

0

5. Dividend

5.1 Amount

FLXN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Flexion Therapeutics

NASDAQ:FLXN (11/18/2021, 7:14:27 PM)

After market: 9.121 +0 (+0.01%)

9.12

-0.02 (-0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap458.42M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.22%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -78.17%
PM (TTM) -100.33%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity -3.04
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.38
Quick Ratio 4.05
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)33.59%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y18.99%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)21.13%
Revenue growth 3Y519.4%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y